Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- ALKS Alkermes+1.8% 6d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Alkermes belongs to, so it often moves with news about it.
- NVS Novartis AG-1.9% 9d
Novartis AG is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+14.8% 30d
AstraZeneca is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- NVO Novo Nordisk A/S+0.1% 30d
Novo Nordisk A/S is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk+0.7% 5d
Gsk is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Alkermes in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ALKS | -1.20% | +1.18% | base | +1.85% | +2.36% | -0.69% | +2.35% |
| XLV | -2.95% | -0.31% | base | -0.34% | +2.73% | +0.31% | +0.13% |
| NVS | -2.88% | -0.25% | base | -1.37% | +2.20% | +0.20% | +0.73% |
| AZN | -8.84% | -6.48% | base | -1.45% | +1.29% | +0.31% | -0.09% |
| NVO | -4.41% | -3.21% | base | -0.61% | +4.24% | -0.96% | -0.38% |
| GSK | +3.75% | -0.94% | base | -0.79% | +4.11% | +2.52% | +2.42% |
| SNY | -7.99% | -5.28% | base | -0.45% | +4.20% | +2.65% | +3.25% |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates Yahoo Finance
Source: Yahoo Finance
This story
| Company | When | Move | Status |
|---|---|---|---|
| ALKS | that day | +1.85% | final price |
| ALKS | the next day | +2.36% | final price |
| ALKS | two days later | -0.69% | final price |
| ALKS | three days later | +2.35% | final price |
| ALKS | three days earlier | +1.18% | final price |
| ALKS | five days earlier | -1.20% | final price |
| AZN | that day | -1.45% | final price |
| AZN | the next day | +1.29% | final price |
| AZN | two days later | +0.31% | final price |
| AZN | three days later | -0.09% | final price |
| AZN | three days earlier | -6.48% | final price |
| AZN | five days earlier | -8.84% | final price |
| GSK | that day | -0.79% | final price |
| GSK | the next day | +4.11% | final price |
| GSK | two days later | +2.52% | final price |
| GSK | three days later | +2.42% | final price |
| GSK | three days earlier | -0.94% | final price |
| GSK | five days earlier | +3.75% | final price |
| NVO | that day | -0.61% | final price |
| NVO | the next day | +4.24% | final price |
| NVO | two days later | -0.96% | final price |
| NVO | three days later | -0.38% | final price |
| NVO | three days earlier | -3.21% | final price |
| NVO | five days earlier | -4.41% | final price |
| NVS | that day | -1.37% | final price |
| NVS | the next day | +2.20% | final price |
| NVS | two days later | +0.20% | final price |
| NVS | three days later | +0.73% | final price |
| NVS | three days earlier | -0.25% | final price |
| NVS | five days earlier | -2.88% | final price |
| SNY | that day | -0.45% | final price |
| SNY | the next day | +4.20% | final price |
| SNY | two days later | +2.65% | final price |
| SNY | three days later | +3.25% | final price |
| SNY | three days earlier | -5.28% | final price |
| SNY | five days earlier | -7.99% | final price |
| XLV | that day | -0.34% | final price |
| XLV | the next day | +2.73% | final price |
| XLV | two days later | +0.31% | final price |
| XLV | three days later | +0.13% | final price |
| XLV | three days earlier | -0.31% | final price |
| XLV | five days earlier | -2.95% | final price |
Congressional trades in the stocks in this story
- Rep. Gilbert Cisneros bought Alkermes (ALKS), worth $1,001 - $15,000 on 29 Sep 2026. That is 35 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 68 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 54 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 64 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 69 days before publication. Filed 17 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates” looks
12 out of 100
“Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates” scores 12 out of 100. The score uses 1 sources.